TACSTD2 and small cell lung carcinoma: Interestingly, elevated TROP2 expression is present in 64% of lung adenocarcinomas, 75% of squamous cell lung cancers, and 18% of high-grade neuroendocrine lung carcinomas (including 10% of SCLC) [18].